Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
PFE

PFE - Pfizer Inc Stock Price, Fair Value and News

27.75USD+0.20 (+0.73%)Delayed
Watchlist

Market Summary

USD27.75+0.20
Delayed
0.73%

PFE Alerts

  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

PFE Stock Price

View Fullscreen

PFE RSI Chart

PFE Valuation

Market Cap

156.7B

Price/Earnings (Trailing)

-112.85

Price/Sales (Trailing)

3.37

EV/EBITDA

22.46

Price/Free Cashflow

32.69

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

2.27%

Return on Equity

-1.56%

Return on Assets

-0.61%

Free Cashflow Yield

3.06%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

46.5B

Rev. Growth (Yr)

703.37%

Rev. Growth (Qtr)

97.99%

PFE Earnings

Earnings (TTM)

-1.4B

Earnings Growth (Yr)

-34.36%

Earnings Growth (Qtr)

105.81%

Breaking Down PFE Revenue

Last 7 days

0.2%

Last 30 days

-3.8%

Last 90 days

-7.7%

Trailing 12 Months

-37.1%

How does PFE drawdown profile look like?

PFE Financial Health

Current Ratio

0.91

Debt/Equity

0.68

Debt/Cashflow

0.14

PFE Investor Care

Dividend Yield

5.95%

Dividend/Share (TTM)

1.65

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202332.7B33.0B23.6B46.5B
202249.9B34.2B32.8B32.6B
202146.1B55.1B68.9B60.9B
202037.9B34.5B32.1B41.7B
201941.0B40.8B40.2B40.9B
201852.7B53.2B53.4B40.8B
201752.6B52.3B52.5B52.5B
201651.0B52.3B53.2B52.8B
201549.1B48.2B47.9B48.9B
201450.5B50.3B50.0B49.6B
201352.7B51.7B51.4B51.6B
201259.7B57.1B53.5B55.2B
201165.1B64.4B65.1B61.3B
201055.0B61.1B65.5B65.2B
200947.3B46.2B45.8B49.3B
200848.4B48.4B48.3B48.3B
200700048.4B

Tracking the Latest Insider Buys and Sells of Pfizer Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 29, 2023
boshoff christoffel
acquired
-
-
34,734
executive vice president
Dec 15, 2023
gottlieb scott
bought
79,401
26.467
3,000
-
May 31, 2023
denton david m
sold (taxes)
-616,798
38.02
-16,223
chief financial officer & evp
May 08, 2023
gottlieb scott
bought
38,580
38.58
1,000
-
May 05, 2023
gottlieb scott
bought
38,425
38.425
1,000
-
Mar 31, 2023
pao william
sold (taxes)
-901,476
40.8
-22,095
executive vice president
Mar 15, 2023
damico jennifer b.
sold
-396,678
40.02
-9,912
svp & controller
Feb 27, 2023
sahni payal
sold (taxes)
-52,891
40.78
-1,297
executive vice president
Feb 27, 2023
mcdermott michael
sold (taxes)
-125,643
40.78
-3,081
executive vice president
Feb 27, 2023
damico jennifer b.
sold (taxes)
-58,193
40.78
-1,427
svp & controller

1–10 of 50

Which funds bought or sold PFE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
209,275
209,275
0.06%
Feb 22, 2024
AUXIER ASSET MANAGEMENT
reduced
-0.79
-332,207
2,059,340
0.33%
Feb 22, 2024
Dodge & Cox
reduced
-1.77
-579,423
3,350,720
-%
Feb 22, 2024
Sentry LLC
new
-
922,086
922,086
0.20%
Feb 22, 2024
PROATHLETE WEALTH MANAGEMENT LLC
new
-
418,891
418,891
0.25%
Feb 21, 2024
WNY Asset Management, LLC
added
3.21
-143,984
1,238,130
0.21%
Feb 21, 2024
V-Square Quantitative Management LLC
added
260
410,876
604,158
0.11%
Feb 21, 2024
Novak & Powell Financial Services, Inc.
new
-
372,701
372,701
0.25%
Feb 21, 2024
CHELSEA COUNSEL CO
reduced
-13.08
-261,262
802,666
0.43%
Feb 21, 2024
Raleigh Capital Management Inc.
reduced
-3.4
-357,746
1,856,390
0.86%

1–10 of 45

Are Funds Buying or Selling PFE?

Are funds buying PFE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PFE
No. of Funds

Unveiling Pfizer Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.97%
506,479,807
SC 13G/A
Jan 29, 2024
state street corp
5.10%
287,875,814
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
434,748,255
SC 13G/A
Feb 09, 2023
vanguard group inc
8.94%
501,636,220
SC 13G/A
Feb 07, 2023
state street corp
5.08%
284,943,697
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
442,868,761
SC 13G/A
Feb 14, 2022
state street corp
5.09%
285,771,591
SC 13G/A
Feb 10, 2022
vanguard group inc
8.29%
465,274,925
SC 13G/A
Feb 01, 2022
blackrock inc.
7.3%
409,985,645
SC 13G/A
Feb 12, 2021
state street corp
5.03%
279,831,373
SC 13G

Recent SEC filings of Pfizer Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
S-3ASR
S-3ASR
Feb 23, 2024
S-8
Employee Benefits Plan
Feb 22, 2024
10-K
Annual Report
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

What is the Fair Value of PFE?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Pfizer Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.7B
93.0B
-3.60% -2.76%
11.09
4.19
6.46% 95.94%
156.7B
46.5B
-3.76% -37.06%
-112.85
3.37
42.59% -114.62%
155.0B
28.2B
-7.44% 18.02%
23.07
5.5
7.09% 2.52%
91.6B
27.1B
-17.13% -16.65%
16.18
3.38
-0.60% 23.36%
14.4B
15.8B
15.02% 26.90%
-25.85
0.91
6.17% 77.01%
MID-CAP
4.9B
1.7B
14.11% 18.79%
13.89
2.97
49.61% 324.78%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.4B
8.8B
-0.23% 18.85%
-5.66
0.38
7.79% -163.11%
2.6B
601.3M
-0.28% 70.16%
18.9
4.25
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.91
1.86
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
22.4M
84.1M
58.23% -28.98%
-1.05
0.22
2882.68% -145.15%
16.2M
111.1M
-6.33% -18.68%
-1.02
0.15
-10.43% 84.90%
2.2M
20.0M
-35.83% -91.10%
-0.16
0.11
137.71% 66.04%

Pfizer Inc News

Latest updates
MSN6 hours ago
InvestorsObserver20 Feb 202405:30 pm
Yahoo Finance07 Feb 202408:00 am
Yahoo Finance07 Feb 202408:00 am

Pfizer Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue98.0%26,19813,2323,4903,6273,26122,6383,2183,5263,42024,03518,89914,51611,42710,2779,86410,0831,84312,68013,26413,1181,155
  S&GA Expenses39.4%4,5753,2813,4973,4184,6453,3913,0482,5934,1042,8992,9232,7773,7392,6582,6592,5412,6163,2603,5113,3392,164
EBITDA Margin-71.4%0.21*0.72*0.89*1.17*1.26*1.22*1.13*0.69*0.51*0.43*0.40*0.40*---------
Interest Expenses219.9%1,062332402419321350318453262407353445344387438472341437424385343
Income Taxes17.5%-795-964-71.007152303561,5701,172249-3281,123808-64.00-347422359-1,9823,047-915433-1,536
Earnings Before Taxes-23.2%-4,129-3,3522,2696,2705,2319,00111,4479,0503,8277,8436,9495,6925985703,0262,842-7,86910,7274,1414,323-9,237
EBT Margin-94.8%0.02*0.44*0.69*0.98*1.06*1.02*0.94*0.55*0.40*0.31*0.25*0.21*---------
Net Income105.8%139-2,3823824732118,6082104685788,1463304612211,46951840537.001485,0463,884-393
Net Income Margin46.5%-0.03*-0.06*0.29*0.29*0.29*0.30*0.27*0.19*0.16*0.13*0.05*0.06*---------
Free Cashflow58.6%4,1962,646-2,12273.007,5815,1337,4195,8984,91210,21110,7623,984---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets5.3%226,501215,000220,000196,000197,20541,137195,000183,841181,47646,335169,920158,818154,00044,97544,24445,840167,59446,081156,000155,421159,422
  Current Assets-41.5%43,33374,01273,34750,07851,2595,93267,46654,42059,6936,89048,81439,53335,0676,6147,1368,21332,8037,50547,07345,29049,926
    Cash Equivalents-7.3%2,9173,1482,6322,1664161,3381,8242,5131,9832,0342,4181,8091,8251,6271,8452,1961,3502,8461,8372,0181,225
  Inventory-0.1%10,18910,20410,3109,5418,9819,51310,4549,9799,0598,6408,9488,4938,0209,2958,5648,4237,0688,2228,2338,0297,508
  Net PPE6.0%18,94017,86217,48817,05216,27415,44115,24415,10914,88214,43614,22414,01113,74514,40314,11314,04012,96913,70113,52113,46713,385
  Goodwill31.5%67,78351,52751,57251,47651,37582849,89150,21149,20849,48949,86749,79149,55659,90258,44958,50248,18158,66553,35253,48742,927
Liabilities16.5%137,213117,817120,87594,381101,28822,455107,821101,155104,01310,35199,60589,95390,75610,57610,18710,677104,14810,77696,27496,26395,664
  Current Liabilities53.5%47,79431,13634,64736,56242,1385,23547,41039,26842,6715,13335,66426,65225,9205,2464,9925,52437,3045,24132,03029,42331,858
  Long Term Debt-100.0%-61,04861,35631,70432,88432,62934,29435,65636,19536,25035,35435,34737,00049,78550,52936,28135,95536,04436,16835,73332,909
    LT Debt, Current-0.3%2,2542,2603,5653,5672,5602,5661,2762601,6362,6633,6873,6762,0022,1491,4813371,4622,4312,1394,4714,776
    LT Debt, Non Current1.6%62,00061,04861,35631,70432,88432,62934,29435,65636,19536,25035,35435,34737,00049,78550,52936,28135,95536,04436,16835,73332,909
Shareholder's Equity-7.9%89,28896,93499,293101,23695,66192,89187,46982,68577,46235,70570,31568,86563,47334,15464,57065,34163,44735,19959,92459,15863,758
  Retained Earnings-6.4%118,353126,411128,796131,102125,656122,967116,608111,193103,394102,25296,34695,15890,392100,284100,203101,00097,670100,11394,44093,38889,554
  Additional Paid-In Capital0.1%92,63192,49692,32992,15391,80291,35991,18390,84490,59189,97389,33689,00288,67488,16187,88687,68087,42887,09986,96386,63586,253
Accumulated Depreciation1.7%16,04515,77915,55415,51415,17414,93114,96915,35815,07415,40315,32815,10514,81216,63616,88916,92916,78916,72816,38916,15816,591
Shares Outstanding-100.0%-5,6425,6465,6345,6085,6065,6055,6175,6015,6095,5985,584---------
Minority Interest1.5%274270274266256227261261262279273245235245138133303105357352351
Float-------294,000---223,000---169,000---241,000--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations51.6%5,2403,456-1,2081,2128,5825,9748,1706,5415,91410,82911,2994,5385,6252,0903,5553,1333,7694,5102,6111,6984,738
  Share Based Compensation-19.9%12115114810536413528786.0049629322117228722418757.0023964.00199185241
Cashflow From Investing-1338.3%-10,996888-25,4853,315-4,410-627-11,313567-2,586-10,076-8,137-1,7478,330481-13,011-71.00-2,833-6,760-1,9027,550-764
Cashflow From Financing244.0%5,442-3,77927,174-2,771-5,015-5,7612,520-6,578-3,351-1,101-2,557-2,807-13,787-2,8219,159-2,200-2,4403,273-851-8,467-6,407
  Buy Backs--------2,000-----------8,8655,030

PFE Income Statement

2023-12-31
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Product revenues[1]$ 50,914$ 91,793$ 73,636
Alliance revenues[1]7,5828,5377,652
Total revenues[2]58,496100,33081,288
Costs and expenses:   
Cost of sales[3],[4]24,95434,34430,821
Selling, informational and administrative expenses[3]14,77113,67712,703
Research and development expenses[3]10,67911,42810,360
Acquired in-process research and development expenses1949533,469
Amortization of intangible assets4,7333,6093,700
Restructuring charges and certain acquisition-related costs2,9431,375802
Other (income)/deductions––net(835)217(4,878)
Income from continuing operations before provision/(benefit) for taxes on income[2],[5],[6]1,05834,72924,311
Provision/(benefit) for taxes on income(1,115)3,3281,852
Income from continuing operations2,17231,40122,459
Discontinued operations––net of tax(15)6(434)
Net income before allocation to noncontrolling interests2,15831,40722,025
Less: Net income attributable to noncontrolling interests393545
Net income attributable to Pfizer Inc. common shareholders$ 2,119$ 31,372$ 21,979
Earnings per common share––basic:   
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.38$ 5.59$ 4.00
Discontinued operations––net of tax (in dollars per share)00(0.08)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)0.385.593.92
Earnings per common share––diluted:   
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)0.375.473.93
Discontinued operations––net of tax (in dollars per share)00(0.08)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.37$ 5.47$ 3.85
Weighted-average shares––basic5,6435,6085,601
Weighted-average shares––diluted5,7095,7335,708
[1]See Note 1G.
[2]Earnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note 17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.
[3]Exclusive of amortization of intangible assets.
[4]See Notes 8A and 17A.
[5]2022 v. 2021––The decrease in domestic income is primarily related to net losses on equity securities in 2022 versus net gains on equity securities in 2021, lower net periodic benefit credits and higher restructuring charges and certain acquisition-related costs, partially offset by Paxlovid income and lower acquired IPR&D expenses. The increase in international income is primarily related to Paxlovid and Comirnaty income partially offset by lower net periodic benefit credits.
[6]2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.

PFE Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 2,853$ 416
Short-term investments9,83722,316
Trade accounts receivable, less allowance for doubtful accounts: 2023—$470; 2022—$44911,17710,952
Inventories[1]10,1898,981
Current tax assets3,9783,577
Other current assets5,2995,017
Total current assets43,33351,259
Equity-method investments11,63711,033
Long-term investments3,7314,036
Property, plant and equipment18,94016,274
Identifiable intangible assets[2]64,90043,370
Goodwill[3]67,78351,375
Noncurrent deferred tax assets and other noncurrent tax assets3,7066,693
Other noncurrent assets12,47113,163
Total assets226,501197,205
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2023—$2,254; 2022—$2,56010,3502,945
Trade accounts payable6,7106,809
Dividends payable2,3722,303
Income taxes payable2,3491,587
Accrued compensation and related items2,7763,407
Deferred revenues2,7002,520
Other current liabilities20,53722,568
Total current liabilities47,79442,138
Long-term debt61,53832,884
Pension and postretirement benefit obligations2,1672,250
Noncurrent deferred tax liabilities6401,023
Other taxes payable8,5349,812
Other noncurrent liabilities16,53913,180
Total liabilities137,213101,288
Commitments and Contingencies
Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 202200
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2023—9,562; 2022—9,519478476
Additional paid-in capital92,63191,802
Treasury stock, shares at cost: 2023—3,916; 2022—3,903(114,487)(113,969)
Retained earnings118,353125,656
Accumulated other comprehensive loss(7,961)(8,304)
Total Pfizer Inc. shareholders’ equity89,01495,661
Equity attributable to noncontrolling interests274256
Total equity89,28895,916
Total liabilities and equity$ 226,501$ 197,205
[1]The increase from December 31, 2022 of $1.2 billion reflects an increase of approximately $1.0 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A), and increases for certain products due to new product launches, supply recovery and changes in net market demand. These increases were offset to a large extent by $1.0 billion in inventory write-offs for Paxlovid and Comirnaty.
[2]The increase is primarily due to $28.8 billion for the acquisition of Seagen (see Note 2A) and the $495 million of capitalized milestones described in note (a) above, partially offset by amortization expense of $4.7 billion and impairments of $3.0 billion (see Note 4).
[3]Our goodwill balance continues to be assigned within the Biopharma reportable segment.
PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
 CEO
 WEBSITEwww.pfizer.com
 EMPLOYEES65535

Pfizer Inc Frequently Asked Questions


What is the ticker symbol for Pfizer Inc? What does PFE stand for in stocks?

PFE is the stock ticker symbol of Pfizer Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pfizer Inc (PFE)?

As of Fri Feb 23 2024, market cap of Pfizer Inc is 156.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers. The fair value of Pfizer Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pfizer Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pfizer Inc a good stock to buy?

The fair value guage provides a quick view whether PFE is over valued or under valued. Whether Pfizer Inc is cheap or expensive depends on the assumptions which impact Pfizer Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PFE.

What is Pfizer Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, PFE's PE ratio (Price to Earnings) is -112.85 and Price to Sales (PS) ratio is 3.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pfizer Inc's stock?

In the past 10 years, Pfizer Inc has provided 0.017 (multiply by 100 for percentage) rate of return.